← All trials
NCT06103188
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 2, 2023
- Primary completion
- Oct 19, 2023
- Completion date
- Oct 19, 2023
- First posted
- Oct 26, 2023
- Last posted
- Oct 27, 2023
- Enrollment
- 87
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of JordanLead sponsor
- University of JordanOverall official - principal investigator
- University of JordanReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.